NCT03713190 is a Phase 2 clinical trial of Empagliflozin in End Stage Renal Disease, sponsored by University of Pisa.

Who is sponsoring NCT03713190?

NCT03713190 is sponsored by University of Pisa.

What drugs are being tested in NCT03713190?

Interventions in NCT03713190: Empagliflozin, Placebo.

What condition does NCT03713190 study?

NCT03713190 studies End Stage Renal Disease.

Is NCT03713190 still recruiting?

NCT03713190 is currently completed. Last updated 14 September 2021.

Last reviewed 2021-09-14 · How we verify

NCT03713190

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

Completed Phase 2 Last updated 14 September 2021

What this trial tests

Phase 2 trial testing Empagliflozin in End Stage Renal Disease in 25 participants. Completed in 15 March 2020.

Timeline

10 September 2018

Primary endpoint
15 February 2020

15 March 2020

Quick facts

Lead sponsor	University of Pisa
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	25
Start date	10 September 2018
Primary completion	15 February 2020
Estimated completion	15 March 2020
Sites	1 location across Italy

Drugs / interventions tested

Empagliflozin (empagliflozin) — full drug profile →
Placebo

Conditions studied

End Stage Renal Disease — all drugs for End Stage Renal Disease →

Sponsor

University of Pisa

Who can join

Adults 30 to 70, any sex, with End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Empagliflozin

Trials testing the same drug.

NCT07060417 — Vascular Effects of SGLT2i in Non-diabetic CKD · Phase 2 · not yet recruiting
NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07180745 — Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease · Phase 4 · not yet recruiting

Other recruiting trials for End Stage Renal Disease

Currently open trials in the same condition.

NCT06257134 — Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients. · NA · recruiting
NCT06310161 — Light Therapy in End Stage Kidney Disease · NA · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06422871 — PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis · recruiting
NCT06861816 — Ventilatory Functions and Physical Intolerance in ESRD Adolescents: Response to Program of Walking With Dogs · NA · recruiting

Other University of Pisa trials

Trials by the same sponsor.

NCT07520890 — Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs) · recruiting
NCT07444229 — Team-Based Learning Integrated Into Clinical Simulation in Nursing Students · NA · not yet recruiting
NCT07041983 — 24-h Energy Expenditure and Anti-obesity Medication · enrolling by invitation
NCT07510685 — Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial) · NA · completed
NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03713190 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pisa
Last refreshed: 14 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03713190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing